Bristol Myers Squibb licenses Antibody-Drug Conjugate technology from Lonza

CAR-T Digest - August 2020

07 May 2026: Bristol Myers Squibb licenses Antibody-Drug Conjugate technology from Lonza

Bristol Myers Squibb has expanded its ADC strategy through an exclusive licensing agreement with Lonza, gaining access to the SYNtecan linker-payload platform for development of a next-generation ADC against an undisclosed target
Beyond the linker-payload technology, the deal also includes access to Lonza’s GlycoConnect and HydraSpace platforms, which are designed to enhance ADC stability, conjugation precision, and overall therapeutic performance
Under the agreement, Bristol Myers Squibb will lead the full development and commercialization of the ADC candidate, leveraging Lonza’s specialized ADC technology infrastructure to support the program
The collaboration further strengthens Lonza’s position in the evolving ADC landscape, where advanced linker-payload and conjugation technologies are becoming increasingly important for differentiated ADC development